New Baltimore partnership aims to improve representation of people of color in clinical trials

Black Americans and other people of color have long been underrepresented in clinical trials for emerging medications and therapies — even when they’re more likely to get sick or die from the condition the treatment is meant to target. Despite being twice as likely to die from COVID-19 than white Americans, for example, Black Americans only comprised about 1 in 10 of the participants in the clinical trials for the Moderna and Pfizer/BioNTech vaccines.